abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
EBITDA Margin
234.72%
TTM · Period ending:
HQL EBITDA Margin
Latest reported234.72%period ending
Latest reported234.72%period ending
HQL EBITDA Margin (5192.86% → 234.72%)
Annual ebitda margin
High-resolution chart · PNG
HQL ebitda margin history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| 99.0837% | |
| 100.6132% | |
| 62.2809% | |
| -318.9195% | |
| 152.535% | |
| 314.9705% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 7,359.438% | |
| 6,573.6842% | |
| 559.8901% | |
| -684.7826% | |
| 3,607.7844% | |
| 1,753.8194% | |
| -58.2609% | |
| 5,029.2135% | |
| 2,237.5% | |
| 6,331.1475% | |
| -268.0851% | |
| -109.6045% | |
| -1,250% | |
| 4,746.875% | |
| 5,192.8571% |